Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.
Also called NCT01289119
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 506 participants
- Sponsor
- Registry
-
NCT01289119 -
U1111-1118-3681
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01289119. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2013-03-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Alogliptin
- Intervention (Drug)
- Placebo to alogliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01289119- Content hash
571a7b4ee6788b8fc2b4dc3be7d5b4b7216fc099d9ce915752b1e8cb73ac6f87